Poor prognosis in cholangiocarcinoma patients with low FBXW7 expression is improved by chemotherapy

NORIHIRO ISHII1,2, KENICHIRO ARAKI1,2, TAKEHIKO YOKOBORI3, AKIRA WATANABE1,2, MARIKO TSUKAGOSHI1,2, NORIO KUBO1,2, HIDEKI SUZUKI1, FUMIYOSHI SAITO1,2, BOLAG ALTAN1, YASUO HOSOUCHI4, KEN SHIRABE5 and HIROYUKI KUWANO1*

Departments of 1General Surgical Science, 2Hepatobiliary and Pancreatic Surgery and 3Molecular Pharmacology and Oncology, Gunma University, Graduate School of Medicine, Maebashi, Gunma 371-8511; 4Department of Surgery and Laparoscopic Surgery, Gunma Prefecture Saiseikai-Maebashi Hospital, Maebashi, Gunma 371-0821, Japan

Received March 30, 2016; Accepted February 1, 2017

DOI: 10.3892/ol.2017.5946

Abstract. The tumor suppressor FBXW7 has been demonstrated to degrade several oncoproteins, including c-Myc. Although low FBXW7 expression levels are suggested to be a poor prognostic factor in a number of types of solid tumor, the role of FBXW7 in chemosensitivity is controversial. The purpose of the present study was to determine whether FBXW7 expression may be used as a marker for poor prognosis and chemosensitivity in patients with cholangiocarcinoma (CC). FBXW7 expression was investigated by immunohistochemistry in 100 surgically resected CC samples, and the association between FBXW7 expression, clinicopathological factors and prognosis was evaluated. Nuclear FBXW7 expression tended to be lower compared with normal tissues. A total of 54 patients exhibited high expression levels of FBXW7, and 46 patients exhibited low expression levels. Patients with low FBXW7 expression possessed significantly larger tumors (P=0.049), enhanced expression of c-Myc and Ki-67 and significantly poorer prognoses compared with those with high FBXW7 expression (P=0.016). Multivariate analysis revealed that low FBXW7 expression was an independent negative prognostic factor in CC (P=0.043). In patients with high FBXW7 expression levels, the cancer-specific survival times were significantly longer in subjects who underwent chemotherapy compared with those who did not (P=0.001). These data suggest that FBXW7 status in CC is a useful predictor of poor prognosis and cancer progression. Additionally, FBXW7 may be a surrogate marker to predict the efficacy of chemotherapy in CC.

Introduction

The incidence of cholangiocarcinoma (CC), which is a major cause of cancer-associated mortality in Asia, is rising worldwide (1). Despite recent advances in cancer therapy, it is difficult to completely cure CC as radical surgical resection is the only effective curative treatment (2). Additionally, chemotherapy regimens for patients with CC with recurrent and metastatic lesions have been insufficient. However, small populations of patients with CC have obtained significant benefits from conventional chemotherapy (3,4). Therefore, to improve patient prognoses and risk assessments, additional studies are required to identify novel markers and therapeutic targets.

F-box and WD repeat domain-containing 7 (FBXW7), which is an F-box protein consisting of 1 of the 4 subunits of the Skp Cullin F-box containing ubiquitin ligase complex, induces the degradation of oncoproteins including c-Myc, CyclinE, mammalian target of rapamycin (mTOR), Notch and myeloid cell leukemia 1 (MCL1) via ubiquitin-mediated degradation pathways (5,6). The degradation of c-Myc by FBXW7 leads to cell cycle dormancy or the G0 state, therefore, FBXW7 alteration serves an important role in, and is a major cause of, carcinogenesis (7). Takeishi et al (8) revealed that ablation of the FBXW7 gene in mouse leukemia-initiating cells of chronic myeloid leukemia induced cell cycle re-entry via accumulation of c-Myc, and subsequently increased the sensitivity of the cells to chemotherapy. Concomitantly, it is known that loss of FBXW7 function is associated with resistance to anti-tubulin agents via the accumulation of the anti-apoptotic protein MCL1, a member of the B-cell lymphoma 2 family (9). Therefore, the role of FBXW7 in chemosensitivity is controversial.
In a previous study of clinical samples, low FBXW7 expression levels were associated with poor prognosis and cancer progression in a number of human malignancies including breast cancer (10), hepatocellular (11) and esophageal carcinoma (12,13). In intrahepatic and perihilar CC, it was demonstrated that low FBXW7 expression levels are associated with cancer progression and the increase of migration and invasion rates due to the accumulation of mTOR, an FBXW7 degradation target, as demonstrated in vivo and in vitro (14). Furthermore, Enkhold et al (15) revealed that low FBXW7 expression levels in clinical samples of intrahepatic CC were associated with significantly poor prognosis, although their number of cases was small. However, few studies have addressed the role of FBXW7 in the prognosis and chemosensitivity of patients with CC, whether intrahepatic or extrhepatic disease.

The purpose of the present study was to determine the clinical significance of FBXW7 expression in CC. The expression levels of FBXW7 were investigated in CC tissue samples using immunohistochemistry to evaluate whether this protein qualifies as a marker of poor prognosis and chemosensitivity for patients with this disease.

Materials and methods

Patients and samples. A total of 100 patients with CC who underwent surgical resection at the Gunma University Hospital (Maebashi, Japan) and the Gunma Prefecture Sai-seikai-Maebashi Hospital (Maebashi, Japan) between January 1996 and December 2011 were included in the present study. There were 69 males and 31 females. The mean age of patients was 68.1 years, range, 36-94 years. Intra- and extrhepatic CC were diagnosed in 14 and 86 patients, respectively. Operative procedures were as follows: Among patients diagnosed with intrahepatic CC, 11 underwent right or left hepatectomy and 3 underwent sectionectomy, and among those diagnosed with extrhepatic CC, 14 underwent hepatectomy with bile duct resection, 63 underwent pancreatoduodenectomy, 3 underwent hepato-pancreatoduodenectomy and 6 underwent bile duct resection alone. For all cases, lymph node dissection was performed according to the location of the tumor. The median follow-up period for survivors was 30.4 months, range, 2.2-115.2 months. The pathological stage of CC was determined according to the 7th edition of tumor-node-metastasis (TNM) classification of Union for International Cancer Center (16). A total of 80 patients were staged as R0, no local residual tumor, and 20 patients were staged as R1, microscopic residual tumor. Recurrence occurred in 56 patients, while 64 patients received chemotherapy. Chemotherapy was recommended for all patients, however, those with dysfunction of the vital organs and those who chose not to receive chemotherapy were excluded. The details of chemotherapy are as follows: 30 patients received tegafur/gimeracil/oteracil (S-1), 24 received gemcitabine, 17 received tegafur-uracil, 7 received gemcitabine + S-1, and 2 received gemcitabine + cisplatin, including overlap. None of the patients had received neoadjuvant chemotherapy and irradiation prior to surgical resection. Patient backgrounds are summarized in Table I. Written informed consent was obtained from all patients included in the present study, which was approved by the institutional review board at Gunma University Hospital.

Immunohistochemical staining. A paraffin-embedded block of CC specimens was cut into 2-µm thick sections and mounted on glass slides. Each section was deparaffinized by xylene and dehydrated in alcohol. Endogenous peroxidase was inhibited using 0.3% H2O2/methanol for 30 min at room temperature. The sections were soaked in heated water with 0.5% Immunosaver (Nissin EM Co. Ltd., Tokyo, Japan) at 98°C for 45 min. Non-specific antigens were blocked by Protein Block, Serum-Free (Dako; Agilent Technologies, Inc., Santa Clara, CA, USA) at room temperature for 30 min. Subsequent to washing in PBS, the Histofine Simple Stain MAX-PO (MULTI) kit (Nichirei Biosciences, Inc., Tokyo, Japan) was applied for visualizing primary antibody and incubated at room temperature for 45 min. The chromogen 3,3′-diaminobenzidine tetrahydrochloride (DAB) was applied as a 0.02% solution containing 0.005% H2O2 in 50 mM ammonium acetate-citrate acid buffer (pH 6.0). Finally, counterstaining of the nucleus was performed using Mayer's hematoxylin solution. A negative control was included by replacing the primary antibody with PBS in 0.1% bovine serum albumin, and confirmed no detectable staining in this case.

Additionally, 3 sequential sections of each sample were treated with primary antibodies against c-Myc (cat. no., ab32072; dilution, 1:50; Abcam) and the cell proliferation marker Ki-67 (cat. no., M7240; dilution, 1:150; Dako; Agilent Technologies, Inc.), according to the aforementioned protocol, to evaluate the correlations between FBXW7, c-Myc and cell proliferation.

Assessment of FBXW7 and c-Myc expression. Nuclear staining of FBXW7 in cancerous tissue was evaluated in 5 randomly selected fields, and the intensity scored. The intensity score ranged from 1 to 3, with 1, weak; 2, moderate; and 3, strong, and was evaluated in each sample.

The expression level of c-Myc was evaluated in the nucleus of the cancerous tissue. The proportion of positively staining tumor cells was evaluated, regardless of the staining intensity. A percentage of positive tumor cells ≥10% was defined as ‘positive’ expression and <10% was defined as ‘negative’ expression (17).

Statistical analysis. Data for the continuous variables were expressed as the mean ± standard deviation, or median and range. The association between FBXW7 expression and clinicopathological characteristics was analyzed using the χ² test and the Wilcoxon signed-rank test. Survival curves were described using the Kaplan-Meier method, and differences in survival between groups were compared using the log-rank test. Univariate and multivariate analysis by the Cox proportional hazards model was used to identify prognostic factors. P<0.05 was considered to indicate a statistically significant difference. All statistical analyses were performed using the JMP software package (version 10.0.0; SAS Institute Inc., Cary, NC, USA).

Results

Analysis of FBXW7 expression in CC tissues by immunohistochemistry. FBXW7 expressed in the nucleus was measured
by immunohistochemistry. Therefore, nuclear FBXW7 expression was evaluated in 100 CC samples. FBXW7 expression was observed in normal bile duct epithelium (Fig. 1A); however, the expression was lower in cancerous areas (Fig. 1B and C). Similarly, FBXW7 expression was reduced at the site of lymph node metastases (Fig. 1D). A total of 54 samples exhibited high FBXW7 expression, whilst 46 exhibited low FBXW7 expression. Additionally, the correlation among FBXW7, c-Myc and marker of proliferation Ki67 (Ki-67) expression was investigated using immunohistochemistry in 3 sequential sections (Fig. 2). Low FBXW7 expression samples demonstrated enhanced expression of c-Myc and Ki-67 (Fig. 2A), while high FBXW7 expression samples exhibited lower expression of c-Myc and Ki-67 (Fig. 2B). Low FBXW7 expression was significantly associated with nuclear c-Myc accumulation (P<0.001).

Association between FBXW7 expression and clinicopathological characteristics of CC. The clinicopathological characteristics of patients listed according to FBXW7 expression are summarized in Table II. Low FBXW7 expression levels were significantly associated with progressive tumor size (P=0.049). Furthermore, the median recurrence-free survival time of the low FBXW7 expression group was significantly shorter compared with that of the high FBXW7 expression group (P=0.044). However, there were no significant differences with respect to age, sex, histology, tumor stage, lymph node metastasis, recurrence and chemotherapy.

Prognostic value of FBXW7 expression in CC. Patients with low FBXW7 expression exhibited significantly poorer prognoses compared with those with high FBXW7 expression in terms of overall and cancer-specific survival (P=0.016 and P=0.007, respectively; Fig. 3A and B). Notably, even in cases of negative lymph node metastasis, the low FBXW7 expression group also exhibited significantly poorer prognosis compared with the high FBXW7 expression group for overall survival (P=0.032; Fig. 3C). The association between FBXW7 expression and survival subsequent to chemotherapy was also examined. In the high FBXW7 expression group, cancer-specific survival times were not significantly different among patients with or without chemotherapy (Fig. 3D). In the low FBXW7 expression group, however, cancer-specific survival times in patients who received chemotherapy were significantly longer compared with that of patients who did not (P=0.001; Fig. 3D). Due to various chemotherapy regimens in the cohort of the present study, a sub-analysis was performed according to chemotherapy regimen, such as S-1, gemcitabine, and tegafur-uracil. However, each regimen demonstrated similar results, and there were no significant differences between the regimens (data not shown). Additionally, the present study considered whether differences in patient characteristics, including exhibiting a more aggressive-stage tumor, may explain the difference in survival outcomes between patients with low FBXW7-expression who underwent chemotherapy compared with those who did not. However, no such differences were observed (Table III). These data therefore suggest that patients with low FBXW7 expression are sensitive to chemotherapy compared with patients with high FBXW7 expression.

Univariate and multivariate analyses of overall survival are summarized in Table IV. Low FBXW7 expression was a prognostic factor on univariate analysis, including with histology, tumor stage, lymph node metastasis and recurrence. However, on multivariate analysis, only low FBXW7 expression in CC was an independent poor prognostic factor, thus outweighing the existing clinicopathological factors for overall survival in the cohort of the present study (P=0.043).

Discussion

In the present study, it was demonstrated that low FBXW7 expression levels in the nucleus are associated with tumor
size and poor prognosis in patients with CC, and is associated
with enhanced c-Myc and Ki-67 expression. Furthermore,
the efficacy of chemotherapy differed according to FBXW7
expression levels, as the low FBXW7 expression group was
more sensitive to chemotherapy compared with the high
FBXW7 expression group.

c-Myc is a target protein of FBXW7, and is regulated
and degraded via ubiquitin-proteasome pathways. Therefore,
the loss of FBXW7 function results in the accumulation of c-Myc (18,19). Additionally, as c-Myc serves an important role in cell cycle regulation, particularly in G0-G1 phase transition (20), the overexpression of c-Myc in tumors is associated with aggressive proliferation (21,22). It has been demonstrated that hematopoietic stem cells from conditional FBXW7 gene knockout mice exhibited c-Myc accumulation, and were therefore difficult to maintain in a quiescent state, leading to excessive acceleration of their cell cycle, exhaustion and even leukemogenesis (23). Additionally, the suppression of FBXW7 by small interference RNA in human colorectal cancer cell lines resulted in enhanced c-Myc expression and increased proliferation (24). In a previous study of clinical samples, low FBXW7 expression correlated with greater tumor size in

Table II. Clinicopathological characteristics according to FBXW7 expression in 100 patients with cholangiocarcinoma.

| Factors                     | FBXW7 expression (%) |   |
|-----------------------------|----------------------|--|
|                             | High (n=54)          | Low (n=46) | P-value |
| Age                         |                      |            | 0.684   |
| ≤65                         | 35 (64.8)            | 28 (60.9)  |         |
| >65                         | 19 (35.2)            | 18 (39.1)  |         |
| Sex                         |                      |            | 0.450   |
| Male                        | 39 (72.2)            | 30 (65.2)  |         |
| Female                      | 15 (27.8)            | 16 (34.8)  |         |
| Histology                   |                      |            | 0.364   |
| Well                        | 14 (25.9)            | 7 (15.2)   |         |
| Moderate                    | 26 (48.2)            | 23 (50.0)  |         |
| Poor                        | 14 (25.9)            | 16 (34.8)  |         |
| Location                    |                      |            | 0.116   |
| Distal                      | 42 (77.8)            | 31 (67.4)  |         |
| Perihilar                   | 8 (14.8)             | 5 (10.9)   |         |
| Intrahepatic                | 4 (7.4)              | 10 (21.7)  |         |
| Tumor size (mm)             |                      |            | 0.049*  |
| ≤60                         | 47 (95.9)            | 37 (84.1)  |         |
| >60                         | 2 (4.1)              | 7 (15.9)   |         |
| Tumor stage                 |                      |            | 0.515   |
| T1, T2                      | 27 (50.0)            | 20 (43.5)  |         |
| T3, T4                      | 27 (50.0)            | 26 (56.5)  |         |
| Lymph node metastasis       |                      |            | 0.591   |
| Absent                      | 30 (55.6)            | 28 (60.9)  |         |
| Present                     | 24 (44.4)            | 18 (39.1)  |         |
| Stage (UICC)                |                      |            | 0.249   |
| 0, I, II                    | 44 (81.5)            | 33 (71.7)  |         |
| III, IV                     | 10 (18.5)            | 13 (28.3)  |         |
| Recurrence                  |                      |            | 0.923   |
| Absent                      | 24 (44.4)            | 20 (43.5)  |         |
| Present                     | 30 (55.6)            | 26 (56.5)  |         |
| Chemotherapy                |                      |            | 0.547   |
| Absent                      | 18 (33.3)            | 18 (39.1)  |         |
| Present                     | 36 (66.7)            | 28 (60.9)  |         |
| Nuclear c-Myc accumulation  |                      |            | <0.001* |
| Negative                    | 42 (77.8)            | 17 (37.0)  |         |
| Positive                    | 12 (22.2)            | 29 (63.0)  |         |
| Recurrence free survival (Months) |                    |            | 0.044*  |
| Median (range)              | 12 (0.5-123.0)       | 7.6 (0.3-83.0) |   |

FBXW7, F-box and WD repeat domain-containing 7; UICC, Union for International Cancer Control. *P<0.05 All P-values were obtained by comparison between high and low FBXW7 expression groups.
gastric cancer and intrahepatic CC (14,25). The present study was consistent with previous findings, as cancer tissue samples with low FBXW7 expression exhibited enhanced nuclear c-Myc and Ki-67 staining. Thus, the data of the present study suggest that the greater tumor sizes observed in the low FBXW7 expression group were caused by an acceleration of the cell cycle, and subsequently of proliferation, due to c-Myc accumulation.

Low levels of FBXW7 protein and/or messenger RNA were revealed to be associated with poor prognoses in breast (10,26), gastric (25), non-small cell lung (27) and esophageal cancer (12,13). The present study demonstrated that low FBXW7 expression in CC was an independent poor prognostic factor that outweighed existing clinicopathological factors, including TNM stage. Thus, the evaluation of FBXW7 expression is a potentially useful marker for predicting prognosis in patients with CC.

Previously, molecular pathways that regulate FBXW7 stability and cellular functions have been investigated extensively. Gene mutation, copy number variations and transcriptional- and post-transcriptional controls are hypothesized to suppress FBXW7 function in cancer (28). FBXW7 gene alterations are often detected in human malignancies, with the rate identified to be ~6% (29). As for mechanisms for the modification of FBXW7 activity other than gene alteration, previous studies have revealed that FBXW7 is regulated by p53 (30,31), microRNA (miR-223 and miR-27) (32,33) and self-ubiquitination in a phosphorylation-dependent manner (34,35). The mutation rate of FBXW7 in CC is ~15-35%, which is as high as in patients with T-cell acute lymphoblastic leukemia (36,37). These data suggest that FBXW7 mutations serve an important role in CC development, and are one of the important suppression mechanisms of FBXW7 in CC. However, the association between FBXW7 mutations and FBXW7 protein expression, as evaluated by immunohistochemistry in the present study, remains unclear and requires additional investigation.

Previous studies have examined the association between FBXW7 and chemosensitivity. It was demonstrated that low FBXW7 expression produced resistance to anti-tubulin agents such as paclitaxel due to MCL1 accumulation (9,27). Additionally, another report revealed that low FBXW7 expression is associated with resistance to doxorubicin in hepatocellular carcinoma (38). However, FBXW7 depletion in leukemia-initiating cells of chronic myeloid leukemia promotes cell cycle re-entry through c-Myc accumulation, and leads to the high sensitivity to imatinib in leukemia-initiating cells and thus enhanced eradication (8). Thus, FBXW7 has a dichotomous

Figure 3. Kaplan-Meier curves of patients with cholangiocarcinoma according to FBXW7 expression. (A) Overall survival rate of patients with low FBXW7 expression was significantly lower compared with that of patients with high FBXW7 expression (P=0.016). (B) Cancer-specific survival rate of patients with low FBXW7 expression was also significantly lower compared with that of patients with high FBXW7 expression (P=0.007). (C) In cholangiocarcinoma patients without lymph node metastasis, patients with low FBXW7 expression exhibited poorer prognosis for overall survival compared with patients with high FBXW7 expression (P=0.032). (D) Cancer-specific survival rate according to the combination of FBXW7 expression and chemotherapy. In the high FBXW7 expression group, no significant difference was observed with respect to survival between patients with or without chemotherapy. In the low FBXW7 expression group, patients without chemotherapy exhibited poorer survival prognoses compared with patients who received chemotherapy (P=0.001). FBXW7, F-box and WD repeat domain-containing 7.
role with respect to chemosensitivity (39). In the present study, the cancer-specific survival in patients with CC with low FBXW7 expression levels who underwent chemotherapy exhibited improved prognosis compared with patients who did not, despite there being no difference in outcomes according to chemotherapy administration in patients with CC with high FBXW7 levels (Fig. 3D). c-Myc accumulation and increased Ki-67 positive cells were also confirmed in the low FBXW7

Table III. Association between clinicopathological characteristics and chemotherapy in patients with low FBXW7 expression.

| Factors                  | Absent (n=18) | Present (n=28) | P-value |
|--------------------------|---------------|----------------|---------|
| Age (≤65 vs. >65)        |               |                | 0.554   |
| Sex (Male vs. Female)    |               |                | 0.639   |
| Histology (Well vs. Poor)|               |                | 0.833   |
| Tumor stage (T1, T2 vs. T3, T4) |   |                | 0.474   |
| Lymph node metastasis Absent vs. Present |   |                | 0.554   |
| Stage (UICC) 0, I, II vs. III, IV |   |                | 0.954   |

Table IV. Univariate and Multivariate analysis for overall survival using the Cox proportional hazards model.

| Variable                          | Univariate analysis | Multivariate analysis |
|-----------------------------------|---------------------|-----------------------|
|                                   | HR                  | 95% CI                | P-value   | HR | 95% CI | P-value   |
| Age (≤65 vs. >65)                 | 1.23                | 0.74-2.00             | 0.404     | -  | -      | -         |
| Sex (Male vs. Female)             | 1.25                | 0.75-2.15             | 0.379     | -  | -      | -         |
| Histology (Well vs. Moderately vs. Poor) | 2.52       | 1.33-5.31             | 0.004*    | 1.83 | 0.93-3.96 | 0.082     |
| Tumor stage (T1-2 vs. T3-4)      | 2.07                | 1.26-3.45             | 0.004*    | 1.57 | 0.91-2.75 | 0.101     |
| Lymph node metastasis (- vs. +)  | 1.86                | 1.14-3.14             | 0.014*    | 1.4  | 0.80-2.46 | 0.229     |
| Recurrence (- vs. +)             | 2.24                | 1.32-3.97             | 0.002*    | 1.56 | 0.90-2.82 | 0.598     |
| FBXW7 (High vs. Low)             | 1.81                | 1.10-2.97             | 0.018*    | 1.67 | 1.01-2.76 | 0.043*    |

HR, hazard ratio; CI, confidence interval; FBXW7, F-box and WD repeat domain-containing 7. *P<0.05.
expression group. Notably, it was demonstrated that the overexpression of c-Myc sensitized pancreatic cancer cell lines to cisplatin (40), and that pediatric medulloblastoma cells are sensitive to chemo- and radiation therapy because of their high c-Myc expression (41). Based on these observations, it appears that c-Myc accumulation as regulated by FBXW7 induces chemosensitivity in patients with clinical CC. The evaluation of FBXW7 expression in CC clinical samples may contribute to predicting the efficacy of chemotherapy and selecting those patients who are expected to benefit from it.

The present study had several limitations, including the retrospective design, single-center cohort and disease heterogeneity, such as intra- and extrahepatic disease, and heterogeneous treatment groups. In particular, as aforementioned, a sample bias of patients according to receipt of chemotherapy was an important issue in the present study, as patients who did not wish to undergo chemotherapy were excluded from the adaptation criteria of chemotherapy. Accordingly, additional studies in larger series, preferably prospective multi-center cohorts, are required to confirm these data.

In conclusion, low expression levels of the cell cycle regulator and tumor suppressor FBXW7 contributed to shorter survival and greater tumor size in patients with CC. The evaluation of FBXW7 expression levels may therefore be a useful predictor of poor prognosis and cancer progression in CC, particularly extrahepatic CC, considering the cohort of the present study. Conversely, low FBXW7 expression was associated with prolonged survival times in patients with CC treated by chemotherapy; this suggests that FBXW7 may be a surrogate marker for predicting the efficacy of chemotherapy in CC.

Acknowledgements

The present study was supported by Grants-in-Aid for Scientific Research from the Japan Society for the Promotion of Science (JSPS; grant numbers 26461969, 15K10129 and 15K10085). The present study was also supported in part by Uehara Zaidan, the Medical Research Encouragement Prize of The Japan Medical Association, the Promotion Plan for the Platform of Human Resource Development for Cancer and New Paradigms - Establishing Centers for Fostering Medical Researchers of the Future programs by the Ministry of Education, Culture, Sports, Science, and Technology of Japan, and Gunma University Initiative for Advanced Research (GIAR).

References

1. Rizvi S and Gores GJ: Pathogenesis, diagnosis and management of cholangiocarcinoma. Gastroenterology 145: 1215-1229, 2013.
2. Blechacz B and Gores GJ: Cholangiocarcinoma: Advances in pathogenesis, diagnosis and treatment. Hepatology 48: 308-321, 2008.
3. Valle JW: Advances in the treatment of metastatic or unresectable biliary tract cancer. Ann Oncol 21 Suppl 7: vii345-vii348, 2010.
4. Valle JW, Furuse J, Jital M, Bearis S, Mizuno N, Wasan H, Bridge-water J and Okusaka T: Cisplatin and gemcitabine for advanced biliary tract cancer: A meta-analysis of two randomised trials. Ann Oncol 25: 391-398, 2014.
5. Davis RJ, Welcker M and Clurman BE: Tumor suppression by the Fbw7 ubiquitin ligase: Mechanisms and opportunities. Cancer Cell 26: 455-464, 2014.
6. Tan Y, Sangaletti O and Spruck C: The Fbxw7/hCdc4 tumor suppressor in human cancer. Cancer Lett 271: 1-12, 2008.
7. Onoyama and Nakayama KI: Fbxw7 in cell cycle exit and stem cell maintenance: Insight from gene-targeted mice. Cell Cycle 7: 3307-3313, 2008.
8. Takeishi S, Matsumoto A, Onoyama I, Naka K, Hirao A and Nakayama KI: Ablation of Fbxw7 eliminates leukemia-initiating cells by preventing quiescence. Cancer Cell 23: 347-361, 2013.
9. Wertz IE, Kusam S, Lam C, Okamoto T, Sandoval W, Anderson DJ, Helgason E, Ernst JA, Eby M, Liu J, et al: Sensitivity to antitubulin chemotherapeutics is regulated by MCL1 and Fbxw7. Nature 471: 135-144, 2011.
10. Ibusuki M, Yamamoto Y, Shinniri S, Ando Y and Iwase H: Reduced expression of ubiquitin ligase FBXW7 mRNA is associated with poor prognosis in breast cancer patients. Cancer Sci 102: 439-445, 2011.
11. Hidaka S, Tovuu LO, Utsunomiya T, Morine Y, Ikemoto T, Arakawa Y, Kanamoto M, Iwashashi S, Saito Y, Takasu C, et al: The role of Fbxw7 expression in hepatocellular carcinoma and adjacent non-tumor liver tissue. J Gastroenterol Hepatol 29: 1822-1829, 2014.
12. Yokobori T, Mimori K, Iwatsuki M, Ishii H, Tanaka F, Sato T, Toh H, Sudo T, Iwaya T, Tanaka Y, et al: Copy number loss of FBXW7 is related to gene expression and poor prognosis in esophageal squamous cell carcinoma. Int J Oncol 41: 253-259, 2012.
13. Kurashige J, Watanebe M, Iwatsuki M, Kinoshita K, Saito S, Hiyoshi Y, Kamohara H, Baba Y, Mimori K and Baba H: Overexpression of microRNA-223 regulates the ubiquitin ligase FBXW7 in oesophageal squamous cell carcinoma. Br J Cancer 106: 182-188, 2012.
14. Yang H, Lu X, Liu Z, Chen L, Xu Y, Wang Y, Wei G and Chen Y: FBXW7 suppresses epithelial-mesenchymal transition, stemness and metastatic potential of cholangiocarcinoma cells. Oncotarget 6: 6310-6325, 2015.
15. Enkhbold C, Utsunomiya T, Morine Y, Ihura S, Ikemoto T, Arakawa Y, Kanamoto M, Iwashashi S, Saito Y, Ishikawa D and Shimada M: Loss of FBXW7 expression is associated with poor prognosis in intrahepatic cholangiocarcinoma. Hepatol Res 44: E346-E352, 2014.
16. TNM classification of malignant tumors. Int Union Against Cancer (UICC): 7th ed. New York: Wiley-Liss; 2009.
17. Huang W, Guo L, Liu H, Zheng B, Ying J and Lv N: c-MYC overexpression predicts aggressive transformation and a poor outcome in mucosa-associated lymphoid tissue lymphomas. Int J Clin Exp Pathol 7: 5634-5644, 2014.
18. Welcker M, Orian A, Jin J, Grim JE, Harper JW, Eisenman RN and Clurman BE: The Fbw7 tumor suppressor regulates glycogen synthase kinase 3 phosphorylation-dependent c-Myc protein degradation. Proc Natl Acad Sci USA 101: 9085-9090, 2004.
19. Yada M, Hatakeyama S, Kamura T, Nishiyama M, Tsunematsu R, Imaki H, Ishida N, Okumura F, Nakayama K and Nakayama KI: Phosphorylation-dependent degradation of c-Myc is mediated by the F-box protein FBXW7. EMBB J 23: 2161-2125, 2004.
20. Imamura AM and Dalton SJ: The cell cycle and Myc intersect with mechanisms that regulate pluripotency and reprogramming. Cell Stem Cell 5: 141-149, 2009.
21. Spencer CA and Groudine M: Control of c-Myc regulation in normal and neoplastic cells. Adv Cancer Res 56: 1-48, 1991.
22. Grandori C, Cowley SM, James LP and Eisenman RN: The Myc/Max/Maf network: Insight from gene-targeted mice. Cell Cycle 7: 3307-3313, 2008.
23. Yokobori T, Mimori K, Iwatsuki M, Ishii H, Yokobori T, Takasu K, Toh H, Onoyama I, Nakayama KI, Baba H and Mori M: Loss of FBXW7, a cell cycle regulating gene, in colorectal cancer: Clinical significance. Int J Cancer 126: 1828-1837, 2010.
24. Yokobori T, Mimori K, Iwatsuki M, Ishii H, Onoyama I, Fukagawa T, Kuroh K, Nakayama KI and Mori M: P53-Altered FBXW7 expression determines poor prognosis in gastric cancer cases. Cancer Res 69: 3788-3794, 2009.
25. Mao JH, Kim JJ, Wu D, Climenti J, Kang HC, DelRosario R and Balmain A: FBXW7 targets mTOR for degradation and cooperates with PTEN in tumor suppression. Science 321: 1499-1502, 2008.
26. Yokobori T, Yokoyama Y, Mogi A, Endoh M, Ito K, et al: FBXW7 regulates antitubulin chemotherapeutic sensitivity and prognosis in NSCLCs. Mol Cancer 12: 328, 2013.
27. Wang L, Ye X, Liu Y, Wei W and Wang Z: aberrant expression of FBXW7 in cancer. Oncotarget 5: 2000-2015, 2014.
29. Akhoondi S, Sun D, von der Lehr N, Apostolidou S, Klotz K, Maljukova A, Cepeda D, Fiegl H, Dafou D, Marth C, et al: FBXW7/hCDC4 is a general tumor suppressor in human cancer. Cancer Res 67: 9006-9012, 2007.

30. Kimura T, Gotoh M, Nakamura Y and Arakawa H: HCDC4b, a regulator of cyclin E, as a direct transcriptional target of p53. Cancer Sci 94: 431-436, 2003.

31. Mao JH, Perez-Losada J, Wu D, Delrosario R, Tsunematsu R, Nakayama KI, Brown K, Bryson S and Balmain A: Fbxw7/Cdc4 is a p53-dependent, haploinsufficient tumour suppressor gene. Nature 432: 775-779, 2004.

32. Xu Y, Sengupta T, Kukreja L and Minella AC: MicroRNA-223 regulates cyclin E activity by modulating expression of F-box and WD-40 domain protein 7. J Biol Chem 285: 34439-34446, 2010.

33. Ji S, Qin Y, Shi S, Liu X, Hu H, Zhou H, Gao J, Zhang B, Xu W, Liu J, et al: ERK kinase phosphorylates and destabilizes the tumor suppressor FBW7 in pancreatic cancer. Cell Res 25: 561-573, 2015.

34. Cheng Y and Li G: Role of the ubiquitin ligase FBw7 in cancer progression. Cancer Metastasis Rev 31: 73-87, 2012.